• Thu news: Industry M&A volume down 8% over 2023. Pfizer’s Ibrance improves breast cancer survival. Lonza shedding capsule biz. AZ’s Lynparza in early breast cancer. Trump wants childhood vaccine discussion. See more on our front page

Sanofi Genzyme insights

Quote

anonymous

Guest
Hello all -

I can't tell if this board is active or legacy, but I'm hoping to get some insights into Sanofi Genzyme after being contacted by a recruiter. Looking for candid and fair perspectives.

I know of some changes like David Meeker left last year and the current purchase of Bioverativ (which will presumably be folded into Genzyme?).

What is it like at Sanofi Genzyme and how do they treat their reps? How is management, how is the leadership, how is the culture, what is your outlook, etc.?

Is one sales team or region better than others? Can you make money?

Thanks!
 






I know this is very uncafepharma BUT.......
Great company to work with, Most managers I have been in contact with treat us like professionals, this is not a babysitting service is is run like a company! good products, good culture decent pay and nice people
 












Meeker leaving was a big blow to the culture. Sanofi is pulling Genzyme into the big pharma world but overall still a good culture. Meeker fought really hard to keep sanofi out so him leaving is tough. Need to be sure manager is from Genzyme or other small biotech
 






Pharma reps need to learn this is a business. High pay and low expectations are gone. Culture is achieved by making numbers and money.

If the launch does not go well, pressure will come down and people will need to act to CYA.
 






The best thing that Genzyme is good for, is giving you a main frame for biotech/rare experience. There are more and more openings and they're not filling them. People are leaving right out of training because they can make 30-40k more. But they got experience. The company says they're looking into pay raises to actually maintain talent and for once get talent from similar biotechs. But we know how that will go. All talk, and be grateful for your 1% raise.

Meanwhile, everyone has left for the competition and will end up bankrupting Genzyme.
 












anonymous said:
The best thing that Genzyme is good for, is giving you a main frame for biotech/rare experience. There are more and more openings and they're not filling them. People are leaving right out of training because they can make 30-40k more. But they got experience. The company says they're looking into pay raises to actually maintain talent and for once get talent from similar biotechs. But we know how that will go. All talk, and be grateful for your 1% raise.

Meanwhile, everyone has left for the competition and will end up bankrupting Genzyme.
Click to expand...
There was a witch hired in Pittsburgh. Is she still there? She jumped around to many companies and was always trouble.
 


















anonymous said:
what do you do all day???
Click to expand...

There is a good amount of spinning your wheels, but we do a good number of weekends and weeknights for patient meetings. In addition to the dinner program requirements. This job is quite complicated, and is more work than any pharma gig.

It's a shame it's tanking with new leadership.They say they stay competitive, but the 25% that have left say otherwise. It's a great place to get your feet wet and move on.
 






Genzyme is no more, hasn’t been. It’s Sanofi Genzyme and when Meeker left that was the sign that the ship was sinking. They are going thru a very silent series of lay offs or “down sizing” with out officially announcing it.
 






anonymous said:
Genzyme is no more, hasn’t been. It’s Sanofi Genzyme and when Meeker left that was the sign that the ship was sinking. They are going thru a very silent series of lay offs or “down sizing” with out officially announcing it.
Click to expand...

Which divisions? Oncology, rare , MS?
It seems MS will ne happening since sales are dwindling. It's been rumored for layoffs in rare, but so many have jumped ship, they may not need to. Oncology got some retention bonuses, but who knows. I know the less sense it makes, is the ssnofi way. But any insight you may have would be beneficial.
 






Sanofi is a culture destroyer. Genzyme has held them off for 7 years pretty good. Sanofi controls the money unfortunately. Way better culture than Sanofi but Sanofi has slowly been dismantling leaders in Genzyme over the years . Kinda of like a slowly spreading cancer. Sanofi always wins in the end. Every single company Sanofi has bought or merged with they've destroyed it.
 






anonymous said:
Sanofi is a culture destroyer. Genzyme has held them off for 7 years pretty good. Sanofi controls the money unfortunately. Way better culture than Sanofi but Sanofi has slowly been dismantling leaders in Genzyme over the years . Kinda of like a slowly spreading cancer. Sanofi always wins in the end. Every single company Sanofi has bought or merged with they've destroyed it.
Click to expand...


I am new (<1 yr) to Sanofi & saw the "One Sanofi" branding rolled out: I don't report directly to Paul H, but am a couple of levels below him. Initial impressions from meeting with him, he seems open to new ideas so that's a positive. That said, beware that his goal when hired was to reduce headcount from 105K down to 90K by end 2022; we are at about 96K now, so 6000 more cuts are coming in fiscal 2022-2023: they can't do outright layoffs in socialist FR, so most will hit US sites such as Swiftwater. This is the third time they tried to hire me, and I finally accepted (third time's the charm, I suppose) - so far so good, but I do see more layoffs coming, unfortunately ...
 






anonymous said:
I am new (<1 yr) to Sanofi & saw the "One Sanofi" branding rolled out: I don't report directly to Paul H, but am a couple of levels below him. Initial impressions from meeting with him, he seems open to new ideas so that's a positive. That said, beware that his goal when hired was to reduce headcount from 105K down to 90K by end 2022; we are at about 96K now, so 6000 more cuts are coming in fiscal 2022-2023: they can't do outright layoffs in socialist FR, so most will hit US sites such as Swiftwater. This is the third time they tried to hire me, and I finally accepted (third time's the charm, I suppose) - so far so good, but I do see more layoffs coming, unfortunately ...
Click to expand...


I'm assuming a chunk of it will be from diabetes as well.

I am impressed with the plan to keep the MS reps, and create a rare neurology division until their launch in 2024. It could be a clusterf*ck for them, or totally genius. Time will tell.
MS certainly gets the better end of the deal though with added experience.
 






Top Bottom
Back
Quote